Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Evidence-Based Management Strategies and Provider Guidance First-line management includes slower dose escalation, dietary adjustments (reduced fat and fiber initially), adequate hydration, and anti-diarrheal agents if needed
Clinical Program Leadership: Manage the MARITIME Phase-3 program, collaborating with CROs and investigators to generate robust data
Methods involve (1) monitoring the rate of production of radioactive end products of fatty acid oxidation disorders for radiolabeled precursor fatty acids or (2) measuring by tandem mass spectrometry the disease-specific acylcarnitines produced when stable isotope fatty acid precursors are incubated with cells in the presence of excess L-carnitine
CJC-1295: The Long-Acting GHRH Analog Structure and Development CJC-1295 is a synthetic 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH)
Shah S, Kellman P, Greiser A, Weale P, Zuehlsdorff S, Jerecic R
US$ 20.75
US$ 25.35
US$ 23.36
US$ 21.09
US$ 21.90
